Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


European Regulatory Round-Up: Collaborations And Conflicts Of Interest

Executive Summary

The European Union hopes to streamline procedures for small drug companies, including through electronic submissions and also calls for a collaborative approach to fight antbiotic resistance; French Senate tightens down on health regulators conflicts of interest.

You may also be interested in...

Rx Class Action Suits May Come To France In Response To Mediator Scandal

French Senate offers a class action mechanism that could impose a 50% penalty on drug firms.

Antibiotic Development Incentives Could GAIN Support From Pipeline Survey

A survey showing improvement in the pipeline for new antibiotics could further the growing momentum for legislation that would create more development incentives.

MHRA’s Beneficial EU Relationship And Profitable Synergies With NICE: An Interview With Michael Rawlins

In December, Michael Rawlins was appointed head of the U.K.’s Medicines and Healthcare products Regulatory Agency. He recognizes the MHRA’s mutually beneficial relationship with European counterparts and is looking to safeguard synergies with other national regulatory bodies and NICE.


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts